Hangzhou Huasai Biomedicine Co., Ltd.: Phase 1 study completed, 5 enrolled (Advanced Melanoma)
Hangzhou Huasai Biomedicine Co., Ltd.: Phase 1 study completed, 5 enrolled (Advanced Melanoma). Its enrollment of 5 is below the median of 80 (1st percentile). Dated 23 days ago, it is in the active follow-up window. Score 50/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 5 · 1th percentile of 9,177 ClinicalTrialStartPulse records · 0.1x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Hangzhou Huasai Biomedicine Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01) |
| NCT ID | NCT06941818 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Advanced Melanoma |
| Intervention types | drug |
| Target enrollment | 5 |
| Site countries | China |
| Posted | 2025-04-24 |
| Planned start | 2025-07-10 |
| Event | Completed |
| Event date | 2026-10-01 |
| Last update posted | 2026-10-14 |
| enrollment percentile | 1th of 9,177 (median 80, 0.1x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Hangzhou Huasai Biomedicine Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Hangzhou Huasai Biomedicine Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-14
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Hangzhou Huasai Biomedicine Co., Ltd. and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- Hangzhou Huasai Biomedicine Co., Ltd.'s enrollment: 1st percentile of 9,177 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
50 / 100 Score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
What is the ClinicalTrialStartPulse record for Hangzhou Huasai Biomedicine Co., Ltd.?
Hangzhou Huasai Biomedicine Co., Ltd.'s Phase 1 study (NCT06941818) in Advanced Melanoma, first posted 2025-04-24: completed (2026-10-01), in an update posted 2026-10-14.
How does Hangzhou Huasai Biomedicine Co., Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 5 is below the median (1th percentile); smaller records often move faster and face less competition. It is 23 days old, still within a typical 45-day follow-up window.
Hangzhou Huasai Biomedicine Co., Ltd. vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Hangzhou Huasai Biomedicine Co., Ltd. | NONUS | 5 | 1st | 2026-10-14 |
| Antlia Bioscience, Inc | NONUS | 104 | 61st | 2026-11-04 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
Related records
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor Hangzhou Huasai Biomedicine Co., Ltd. and peer phase 1 records
Get new ClinicalTrialStartPulse records like Hangzhou Huasai Biomedicine Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.